ArgiNOx Phamaceuticals.
Biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies
About ArgiNOx Phamaceuticals.
ArgiNOx Pharmaceuticals, Inc. operated as a specialty pharmaceutical firm concentrating on the discovery and development of drugs for cardiovascular diseases, with a specific focus on treatments for hospitalized patients. Originally incorporated as Juventis, Inc. in 2000, the company was re-established as ArgiNOx Pharmaceuticals in 2002 and was headquartered in Menlo Park, California. The company's scientific foundation was built upon Nobel prize-winning research into the role of nitric oxide (NO) in various physiological functions.
The company's primary business was centered on research and development to manufacture drugs for cardiovascular pathologies. ArgiNOx's lead drug candidate was Tilarginine Acetate Injection, a synthetically produced small molecule designed to inhibit the production of nitric oxide. This therapeutic was developed to treat cardiogenic shock, a life-threatening condition that can occur after a severe heart attack, affecting a significant number of patients who reach the hospital. The business model was typical of a clinical-stage biopharmaceutical company, involving significant investment in research, clinical trials, and regulatory processes, with the ultimate goal of commercializing its proprietary drug candidates.
A significant milestone for ArgiNOx was securing a total of $42 million in funding. This included a Series C funding round on March 1, 2005, where the company raised $25 million from investors including Topspinventure.com and Perseus Soros Biopharmaceutical Fund. Following this, in June 2005, ArgiNOx initiated a pivotal Phase III clinical trial, known as TRIUMPH, for its lead compound, tilarginine. The former president and CEO was Kenneth Drazan. Despite its progress, the company ultimately ceased operations and is now considered defunct.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2000
- Headquarters
- Redwood City, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 22.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Mar 2005 | $25M | $100M | Undisclosed | — |
| SERIES B✓Equity / VC | Jun 2004 | $8M | $32M | Undisclosed | — |
Growth signals
Latest recorded traffic for ArgiNOx Phamaceuticals. is 0 monthly website visits. ArgiNOx Phamaceuticals.'s team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ArgiNOx Phamaceuticals. in the Redwood City ecosystem
The ArgiNOx Phamaceuticals. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ArgiNOx Phamaceuticals. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ArgiNOx Phamaceuticals.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









